RxDoctor Payments DataLook up a doctor →

Brian Morrissey, MD

Pulmonary Disease · Sacramento, CANPI 1992780209

Payments from drug & device makers

$2,289,776in general payments, 2019–2025

Across 719 payments — averaging $3184.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vertex$993K
  • Boehringer Ingelheim$613K
  • Insmed, Inc.$523K
  • Pulmonx Corporation$72K
  • Shire North American Group Inc$36K
  • Boehringer Ingelheim Pharma GmbH & Co.kg$18K
  • plus $35K from 12 others
$3,293in research payments, 2019–2025

Across 17 payments — averaging $193.72 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Insmed, Inc.$3K

What the payments were for

  • Consulting fees$49,85670%
  • Speaking & faculty fees$9,29513%
  • Travel & lodging$9,19113%
  • Food & beverage$2,4123%
  • Education$540%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,289,776 in reported general payments places this provider in the 95th percentile of 1,261 pulmonary disease providers in California.

See all pulmonary disease providers in California

Medicare billing

Part B allowed, 2024
$70,189
Medicare patients
436
Services billed
1,125

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrikaftaElexacaftor/Tezacaftor/Ivacaft85$2,161,395
OfevNintedanib Esylate92$1,186,614
ArikayceAmikacin Liposomal/Neb.Accessr18$263,046
EsbrietPirfenidone25$258,793
CaystonAztreonam Lysine19$216,875
XolairOmalizumab28$112,541
Pirfenidone21$100,711
ZenpepLipase/Protease/Amylase13$55,414
PertzyeLipase/Protease/Amylase12$29,331
Stiolto RespimatTiotropium Br/Olodaterol Hcl13$8,772
Mycophenolate Mofetil18$7,528
SymbicortBudesonide/Formoterol Fumarate25$5,512
Combivent RespimatIpratropium/Albuterol Sulfate12$5,331
Advair HfaFluticasone Propion/Salmeterol17$4,838
Albuterol Sulfate HfaAlbuterol Sulfate47$1,817

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
VertexTrikafta$993,378$2,161,39585 claims
Boehringer IngelheimOfev, Stiolto Respimat, Combivent Respimat$613,118$1,200,717117 claims
Insmed, Inc.Arikayce$523,093$263,04618 claims
Genentech USA, Inc.Esbriet$247$258,79325 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,261 pulmonary disease providers in California.

Other pulmonary disease in Sacramento

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →